World leading insulin Danish manufacturer, , has sued Bioton for patent theft. The insulin pen, GensuPen, which has been distributed by Bioton since autumn of 2010, allegedly breach two European patents designed to protect inventions in medical devices.
We would expect some pressure on Bioton shares in the next couple of weeks. We have not yet heard of the potential size of the fine in case the infringement lawsuit ends negatively for Bioton. Bioton’s GensuPen injection devices are sold in Poland and other foreign markets in Russia and in China (through the agreement with Healthcare Company).